Basal Cell Carcinoma: The Daily PANCE Blueprint
A 68-year-old male with a history of extensive sun exposure presents with a small, pearly nodule on his nose with telangiectasia. Biopsy confirms the diagnosis of basal cell carcinoma (BCC). Which of the following is NOT a treatment option for basal cell carcinoma?
A. Mohs micrographic surgery
B. Topical 5-fluorouracil
C. Topical Imiquimod
D. Bevacizumab
E. Radiation therapy
Answer and topic summary
The answer is D. Bevacizumab
The correct answer is D, Bevacizumab. Bevacizumab is an anti-VEGF monoclonal antibody used primarily for the treatment of various advanced cancers, such as colorectal cancer, lung cancer, and glioblastoma. It is not used in the treatment of basal cell carcinoma, which typically does not require systemic antiangiogenic therapy.
A. Mohs micrographic surgery: This is a highly effective treatment for BCC, especially for lesions in cosmetically sensitive areas or when tissue preservation is paramount.
B. Topical 5-fluorouracil: This topical chemotherapy is used for superficial BCC, particularly when surgical options are contraindicated or for patients with multiple lesions.
C. Topical Imiquimod: This immune response modifier is approved for the treatment of superficial BCC, promoting local immune responses against the tumor cells.
E. Radiation therapy: This is a treatment option for BCC, particularly in older adults who may not be good candidates for surgery or when the carcinoma is located in a difficult-to-treat area.
View blueprint lesson
Smarty PANCE Content Blueprint Review:
Covered under ⇒ PANCE Blueprint Dermatology ⇒ ⇒
Also covered as part of the General Surgery EOR and Family Medicine EOR topic list
